title: Lipid-altering drugs: decreasing cardiovascular disease at the expense of increasing cancer?
authors.forename: Mark R
authors.initials: MR
authors.lastname: Goldstein
authors.forename: Koji
authors.initials: K
authors.lastname: Murao
authors.forename: Hitomi
authors.initials: H
authors.lastname: Imachi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
authors.forename: Norman C W
authors.initials: NC
authors.lastname: Wong
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL